ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0692

Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications

Namita Goyal1, Jonathan Cauchi1, Tyler Irani1, Nadia Araujo1, Leo Wang2, Marie Wencel1, Vivian Li3, Steven Greenberg4 and Tahseen Mozaffar1, 1University of California Irvine, Irvine, CA, 2University of Washington, Seattle, WA, 3University of California, Irvine, CA, 4Brigham and Women's Hospital Department of Neurology, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Biomarkers, Inclusion body myositis, KLRG1, Natural Killer Cells, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The recent discovery of highly differentiated, killer cell lectin-like receptor subfamily G member 1 (KLRG1)+ T cells in the muscle of inclusion body myositis (IBM) patients raises the potential of targeting KLRG1 for therapeutic intervention. High-resolution mapping of blood KLRG1+ T cells and the broader T cell compartment of IBM patients is lacking. Here, we report the deep immunophenotyping of IBM blood T cell compartments and the relationship of derived biomarkers to IBM diagnosis, disease duration, and disease severity.

Methods: Patients providing informed consent who met the European Neuromuscular Centre (ENMC) criteria for clinically defined or probable IBM were included. Functional data and quality of life questionnaires were collected. Serological testing for NT5C1A antibodies and analysis of markers of T cell and NK subsets including KLRG1 isolated from peripheral blood through multiplex flow cytometry were done and compared with data from age-matched healthy donors.

Results: Data were obtained from 51 IBM patients and 19 healthy donors. A population of KLRG1+ T effector memory (TEM) and T effector memory re-expressing CD45RA (TEMRA) cells was expanded in both the CD4+ and CD8+ T cell subpopulations of IBM patients (Figure 1). KLRG1 expression in CD8+ T cells increased with T cell differentiation with the lowest levels in naïve T cells and highest in highly differentiated TEMRA and CD56+CD8+ T cells in IBM. The CD8+ TEMRA and KLRG1+ CD8+ TEMRA proportions were not associated with IBM disease severity, but modestly positively associated with disease duration. The KLRG1+CD4+ cells in IBM patients vs healthy controls had high diagnostic performance (area under the curve=0.96; p< 0.0001) (Table 1). Minimal KLRG1 expression was present on regulatory T cells (3%) and no apparent alterations in NK cell phenotypes were identified in IBM.

Conclusion: Our findings reveal an expansion of blood KLRG1+ CD4+ and CD8+ TEMRA and TEM cells in IBM. Lack of association with disease activity suggests these cells may have a pathogenic role throughout the entire disease course. Measurement of these cells potentially allows for new blood diagnostic biomarkers.

Table 1. Diagnostic performance of blood biomarkers of IBM

Figure 1. Skewed distribution of the blood T cell population in IBM towards highly differentiated CD8+ cytotoxic T cells. (A) Expansion of the KLRG1+ populations among total CD3+ T cells, Tregs, CD4+ T cells, and CD8+ T cells. (B) The proportion of blood naïve and early differentiated T cells (CD57-CD28+) and heterogenous highly differentiated T cells (CD57-CD28-; CD57+CD28-; CD57+CD28+) among CD4+ Tconv and CD8+ T cells. (C) KLRG1 expansion within and CD8+ TEM4 and TEMRA populations. (D) Expansion of the KLRG1+ T cell population lies largely within the highly differentiated compartments.


Disclosures: N. Goyal, None; J. Cauchi, None; T. Irani, None; N. Araujo, None; L. Wang, None; M. Wencel, None; V. Li, None; S. Greenberg, Abcuro, Inc., 1, 2, 8, 10; T. Mozaffar, None.

To cite this abstract in AMA style:

Goyal N, Cauchi J, Irani T, Araujo N, Wang L, Wencel M, Li V, Greenberg S, Mozaffar T. Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/immunophenotyping-of-inclusion-body-myositis-blood-t-cells-pathogenic-and-biomarker-implications/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunophenotyping-of-inclusion-body-myositis-blood-t-cells-pathogenic-and-biomarker-implications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology